PDS Biotechnology Corp has announced a significant stock option grant to its Chief Scientific Officer, Spencer Brown, as detailed in a recent SEC filing. This move is designed to align the interests of key personnel with the company's long-term goals and performance metrics.
The stock option grant, which involves 299,567 shares, is contingent upon stockholder approval of the Issuer's 2026 Equity Incentive Plan. The filing specifies that the option was granted on November 16, 2026, and will not be exercisable until such approval is obtained. If stockholder approval is secured, the shares will vest in equal monthly installments over four years, starting December 16, 2026, provided that Brown remains with the company.
Background
PDS Biotechnology Corp, incorporated in Delaware, operates within the pharmaceutical preparations industry, classified under SIC code 2834. The company trades on the Nasdaq under the ticker symbol PDSB. Its headquarters is located at 303A College Road East, Princeton, NJ. PDS Biotechnology focuses on developing innovative therapies for cancer and infectious diseases.
What the Filing Says
The SEC filing, accession number 0001140361-26-044526, indicates that the stock option grant is part of a broader strategy to motivate and retain top talent within the company. The filing notes, “The option is not exercisable until stockholder approval has been obtained.”
Impact
This development may affect the company's workforce dynamics, particularly in retaining key personnel who are essential to its research and development efforts. Additionally, it highlights the competitive landscape within the pharmaceutical industry, where attracting and keeping top talent is crucial for success.
What's Next
Following this filing, the next step involves seeking stockholder approval for the 2026 Equity Incentive Plan. The outcome of this vote will determine whether the stock options can be exercised and may influence future compensation strategies within the company.
Read Next
TripAdvisor's Kristen Dalton Reports Multiple Stock Transactions
PDS Biotechnology CEO Reports Major Stock Option Transactions
EverCommerce CFO Acquires 1,067 Shares of Company Stock
Kunins reports stock transaction at Axon Enterprise, Inc.
TripAdvisor CEO Matt Goldberg Reports Stock Transactions
PDS Biotechnology's Spencer Brown Exercises 150,000 Stock Options










